Skip to content

Study · Non-randomized trial · 2000

6 results

[Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease].

Polunin GS, Nurieva SM, Baiandin DL, Sheremet NL, Andreeva LA

Vestnik oftalmologii1 Jan 2000Cited by 5 (Europe PMC)

PMID10741256 (opens in a new tab)PepBankPUB-10741256
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with optic nerve disease, adding semax to the therapeutic complex had a favorable impact on the intensity and rate of recovery.

    In plain wordsIn patients with optic nerve disease, adding semax to usual treatment helped recovery be stronger and faster.

    Peptide
    Semax
    Outcome
    IncreaseIntensity and rate of recovery in optic nerve disease
    Study

    n: not reported in source

    Comparator
    Basic therapy without semax (control group)
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated · intranasal drops or endonasal electrophoresisAs given in this study (human).

    Source sentences

    Summary
    Addition of semax to therapeutic complex in patients with diseases of the optic nerve had a favorable impact on the intensity and rate of recovery
    2 context sentences
    Summary · context
    It was used in the treatment of vascular, toxic allergic, and inflammatory diseases of the optic nerve and partial atrophy of the optic nerve in parallel with basic neurotrophic and antiinflammatory therapy.
    Summary · context
    In group 1 semax was administered intransally as nasal drops, in group 2 by endonasal electrophoresis, and group 3 was control.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with optic nerve disease, adding semax to the therapeutic complex improved visual functions.

    In plain wordsIn patients with optic nerve disease, adding semax to usual treatment improved vision.

    Peptide
    Semax
    Outcome
    IncreaseVisual functions
    Study

    n: not reported in source

    Comparator
    Basic therapy without semax (control group)
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated · intranasal drops or endonasal electrophoresisAs given in this study (human).

    Source sentences

    Summary
    and improved the visual functions.
    2 context sentences
    Summary · context
    It was used in the treatment of vascular, toxic allergic, and inflammatory diseases of the optic nerve and partial atrophy of the optic nerve in parallel with basic neurotrophic and antiinflammatory therapy.
    Summary · context
    In group 1 semax was administered intransally as nasal drops, in group 2 by endonasal electrophoresis, and group 3 was control.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with optic nerve disease, semax was linked to improved visual acuity.

    In plain wordsIn patients with optic nerve disease, semax was linked to better visual acuity.

    Peptide
    Semax
    Outcome
    IncreaseVisual acuity
    Study

    n: not reported in source

    Comparator
    Basic therapy without semax (control group)
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated · intranasal drops or endonasal electrophoresisAs given in this study (human).

    Source sentences

    Summary
    improvement of visual acuity
    2 context sentences
    Summary · context
    It was used in the treatment of vascular, toxic allergic, and inflammatory diseases of the optic nerve and partial atrophy of the optic nerve in parallel with basic neurotrophic and antiinflammatory therapy.
    Summary · context
    In group 1 semax was administered intransally as nasal drops, in group 2 by endonasal electrophoresis, and group 3 was control.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with optic nerve disease, semax was linked to extension of the total visual field.

    In plain wordsIn patients with optic nerve disease, semax was linked to a wider visual field.

    Peptide
    Semax
    Outcome
    IncreaseTotal visual field
    Study

    n: not reported in source

    Comparator
    Basic therapy without semax (control group)
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated · intranasal drops or endonasal electrophoresisAs given in this study (human).

    Source sentences

    Summary
    extension of the total visual field
    2 context sentences
    Summary · context
    It was used in the treatment of vascular, toxic allergic, and inflammatory diseases of the optic nerve and partial atrophy of the optic nerve in parallel with basic neurotrophic and antiinflammatory therapy.
    Summary · context
    In group 1 semax was administered intransally as nasal drops, in group 2 by endonasal electrophoresis, and group 3 was control.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with optic nerve disease, semax was linked to an increase in the electric sensitivity and conductivity of the optic nerve.

    In plain wordsIn patients with optic nerve disease, semax was linked to better electrical sensitivity and signal conduction of the optic nerve.

    Peptide
    Semax
    Outcome
    IncreaseElectric sensitivity and conductivity of the optic nerve
    Study

    n: not reported in source

    Comparator
    Basic therapy without semax (control group)
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated · intranasal drops or endonasal electrophoresisAs given in this study (human).

    Source sentences

    Summary
    increase in the electric sensitivity and conductivity of the optic nerve
    2 context sentences
    Summary · context
    It was used in the treatment of vascular, toxic allergic, and inflammatory diseases of the optic nerve and partial atrophy of the optic nerve in parallel with basic neurotrophic and antiinflammatory therapy.
    Summary · context
    In group 1 semax was administered intransally as nasal drops, in group 2 by endonasal electrophoresis, and group 3 was control.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with optic nerve disease, semax was linked to improved color vision.

    In plain wordsIn patients with optic nerve disease, semax was linked to better color vision.

    Peptide
    Semax
    Outcome
    IncreaseColor vision
    Study

    n: not reported in source

    Comparator
    Basic therapy without semax (control group)
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated · intranasal drops or endonasal electrophoresisAs given in this study (human).

    Source sentences

    Summary
    improvement of color vision.
    2 context sentences
    Summary · context
    It was used in the treatment of vascular, toxic allergic, and inflammatory diseases of the optic nerve and partial atrophy of the optic nerve in parallel with basic neurotrophic and antiinflammatory therapy.
    Summary · context
    In group 1 semax was administered intransally as nasal drops, in group 2 by endonasal electrophoresis, and group 3 was control.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.